Search Results

You are looking at 161 - 170 of 569 items for :

  • Refine by Access: All x
Clear All
Full access

Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update

Diane L. Reidy-Lagunes

administered at 37.5 mg daily (as opposed to the 50-mg dose in the phase II study) because of the increased rate of grade 3 fatigue discussed previously. 2 The study was stopped prematurely by the independent Data Monitoring Committee before the first

Full access

The NCCN Guideline for Distress Management: A Case for Making Distress the Sixth Vital Sign

Jimmie C. Holland and Barry D. Bultz

. 16. Carlson LE Angen M Cullum J . High levels of untreated distress and fatigue in cancer patients . Br J Cancer 2004 ; 90 : 2297 – 2304 . 17. Carlson LE Bultz BD . Cancer distress screening. Needs, models, and methods . J

Full access

Biobehavioral Factors in Chemotherapy-Induced Nausea and Vomiting

Joseph A. Roscoe, Gary R. Morrow, Jane T. Hickok, Karen M. Mustian, and Abhay R. Shelke

exercise on patient reports of nausea . Oncol Nurs Forum 1988 ; 15 : 447 – 450 . 39 Schwartz AL . Daily fatigue patterns and effect of exercise in women with breast cancer . Cancer Pract 2000 ; 8 : 16 – 24 .

Full access

Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group

Katrine Løppenthin, Christoffer Johansen, Matilde Bille Larsen, Birgitte Hysse Forchhammer, Jannick Brennum, Karin Piil, Neil Aaronson, Birthe Krogh Rasmussen, and Pernille Bidstrup

and its treatment. 2 , 3 Frequent symptoms include global cerebral manifestations (fatigue, nausea, headache, and confusion), focal symptoms (hemiparesis, paresthesia, motor control deficiency, visual disturbances, seizures, and speech difficulties

Full access

Establishing an Anemia Clinic for Optimal Erythropoietic-Stimulating Agent Use in Hematology-Oncology Patients

Jeffrey A. Gilreath, Daniel S. Sageser, James A. Jorgenson, and George M. Rodgers

Assessment of Cancer Therapy—Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue . Semin Hematol 1997 ; 34 ( Suppl 2 ): 13 – 19 . 29. Groopman JE Itri LM . Chemotherapy-induced anemia in adults

Full access

Palliative Care: Who is Responsible?

Amanda M. Rosenblum and Martin R. Chasen

Canadian Problem Checklist (CPC). The ESAS is a questionnaire that asks patients to rate the severity of 9 common symptoms—pain, fatigue, tiredness, nausea, appetite, shortness of breath, depression, anxiety, and well-being—on a visual analogue scale

Full access

Counterpoint: Prostate Cancer Life Expectancy Can Not Be Accurately Predicted From Currently Available Tools

Susan A. McCloskey and Michael R. Kuettel

fatigue . J Natl Cancer Inst Monogr 2004 ; 32 : 119 – 123 . 46. Saliba D Elliott M Rubnstein LZ . The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community . J Am Geriatr Soc 2001 ; 49 : 1691 – 1199

Full access

Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes

Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park

dimensions: physical functioning, bodily pain, role limitations due to physical health problems, personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health. Subscale scores range from 0 to 100, and total

Full access

Optimizing BTK Inhibition in Waldenström Macroglobulinemia

Shayna Sarosiek and Jorge J. Castillo

-naïve WM demonstrated that fatigue, upper respiratory tract infection, hematoma, atrial fibrillation, urinary tract infection, and rash were the most common grade ≥2 adverse events. 12 In another trial, patients with previously treated WM who received

Full access

NCCN News

oncology care to patients with cancer and cancer survivors, including addressing unique needs of LGBTQ+ people with cancer, retaining high-value staff during the current landscape, and reducing the toll from cancer treatment-related fatigue and other